{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:38:33Z","timestamp":1792093113495,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.jcjo.2014.11.006","type":"journal-article","created":{"date-parts":[[2015,4,11]],"date-time":"2015-04-11T06:32:11Z","timestamp":1428733931000},"page":"132-136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study"],"prefix":"10.1016","volume":"50","author":[{"given":"Celine E.","family":"Saade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed B.","family":"Lari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara L.","family":"Berezina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Fechtner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert S.","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2014.11.006_bib1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/IJG.0b013e31815c5f4f","article-title":"Prevalence of ocular surface disease in glaucoma patients","volume":"17","author":"Leung","year":"2008","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jcjo.2014.11.006_bib2","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/01.ico.0000220776.93852.d9","article-title":"Incidence and prevalence of glaucoma in severe ocular surface disease","volume":"25","author":"Tsai","year":"2006","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2014.11.006_bib3","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1136\/bjophthalmol-2013-304619","article-title":"ODISSEY European Consensus Group members. Diagnosing the severity of dry eye: a clear and practical algorithm","volume":"98","author":"Baudouin","year":"2014","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.11.006_bib4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1600-0420.2007.00882.x","article-title":"Use of eye drops in glaucoma: how can we help to reduce non-compliance?","volume":"85","author":"Chawla","year":"2007","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.jcjo.2014.11.006_bib5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.ajo.2006.11.060","article-title":"Impact of dry eye syndrome on vison-related quality of life","volume":"143","author":"Milanovic","year":"2007","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.11.006_bib6","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1097\/ICO.0b013e3181c325b2","article-title":"Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications","volume":"29","author":"Fechtner","year":"2010","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2014.11.006_bib7","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1136\/bjo.86.4.418","article-title":"Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication","volume":"86","author":"Pisella","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.11.006_bib8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0939-6411(01)00246-6","article-title":"Ocular tolerance of preservatives and alternatives","volume":"53","author":"Furrer","year":"2002","journal-title":"Eur J Pharm Biopharm"},{"key":"10.1016\/j.jcjo.2014.11.006_bib9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1097\/ICU.0b013e32835c8aba","article-title":"Glaucoma therapy and ocular surface disease: current literature and recommendations","volume":"24","author":"Anwar","year":"2013","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.11.006_bib10","doi-asserted-by":"crossref","first-page":"34","DOI":"10.5301\/ejo.5000001","article-title":"Comparison of a travoprost BAK-free formulation preserved with poluquaternium-1 with BAK-preserved travoprost in ocular hypertension or open-angle glaucoma","volume":"22","author":"Gandolfi","year":"2012","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.11.006_bib11","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/OPTH.S14113","article-title":"Ocular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprost","volume":"4","author":"Katz","year":"2010","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.11.006_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/IJG.0b013e318264cd68","article-title":"Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control","volume":"23","author":"Batra","year":"2014","journal-title":"J Glaucoma"},{"key":"10.1016\/j.jcjo.2014.11.006_bib13","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1001\/archopht.118.5.615","article-title":"Reliability and validity of the Ocular Surface Disease Index","volume":"118","author":"Schiffman","year":"2000","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.11.006_bib14","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1177\/112067210901900409","article-title":"Dry eye syndrome-related quality of life in glaucoma patients","volume":"19","author":"Rossi","year":"2009","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.11.006_bib15","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","article-title":"Grading of corneal and conjunctival staining in the context of other dry eye tests","volume":"22","author":"Bron","year":"2003","journal-title":"Cornea"},{"key":"10.1016\/j.jcjo.2014.11.006_bib16","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1442-9071.2012.02781.x","article-title":"Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication","volume":"40","author":"Ghosh","year":"2012","journal-title":"Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.11.006_bib17","first-page":"441","article-title":"A multicenter evaluation of ocular surface disease prevalence in patients with glaucoma","volume":"6","author":"Garcia-Feijoo","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.11.006_bib18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2147\/OPTH.S28104","article-title":"Effects of preservative-free tafluprost on tear film osmolarity, tolerability, and intraocular pressure in previously treated patients with open-angle glaucoma","volume":"6","author":"Januleviciene","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.11.006_bib19","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1755-3768.2010.01907.x","article-title":"Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication","volume":"88","author":"Uusitalo","year":"2010","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jcjo.2014.11.006_bib20","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1089\/jop.2010.0060","article-title":"Efficacy and tolerability of preservative free eye drops containing a fixed combination of dorzolamide and timolol in glaucoma patients","volume":"26","author":"Renieri","year":"2010","journal-title":"J Ocul Pharmacol Ther"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418214003901?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418214003901?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:04:19Z","timestamp":1757793859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418214003901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S0008418214003901"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2014.11.006","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2014.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}